Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain
CompletedPhase 4NCT04123652
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
As lidocaine and ketamine provide analgesia by acting on different molecular pathways, administering them together may produce synergistic effects, which can allow for using a lower dose of each medication and thereby reducing the corresponding side effects. To the investigator's knowledge, despite the common practice of multimodal analgesia, lidocaine-ketamine infusions have never been studied prospectively in an out of hospital setting to treat neuropathic pain. The aim of the present study is to evaluate the effectiveness of the current routine practice of lidocaine-ketamine infusions conducted at Allevio Pain Management Clinic, a large outpatient community based chronic pain management facility. Lidocaine-ketamine infusions are prescribed to patients that have pain that is considered to be neuropathic for which standard anti-neuropathic medications have been ineffective or poorly tolerated by patients. A prospective longitudinal study.
Study details
- Official title
- Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain: an Observational Prospective Study
- Conditions
- Chronic Neuropathic Pain and Fibromyalgia
- Interventions
- Drug: Lidocaine Hydrochloride 2% Intravenous Solution, DIN 02421992
- Sponsor
- Allevio Pain Management Clinic
- Start date
- 2017-11-05
- Primary completion
- 2020-11-11
- Sex
- All
- Age range
- from 18 Years to 90 Years
- Results posted
- No results posted in this snapshot
- Countries
- Canada
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: Pain duration \> 3 months; Multifocal and/or non-dermatomal neuropathic pain per Pain Diagram; Failed medical management with at least 2 neuromodulation agents (e.g., gabapentinoids, antidepressants, cannabinoids); Neuropathic component (12 or more points on S-LANSS); Exclusion Criteria: Non-English speakers; Refusal to sign informed consent; Allergy to ketamine and/or lidocaine; Known relative contraindications to ketamine use which include poorly controlled systemic illnesses: hypertension, hyperthyroidism, ischemic heart disease, heart failure, psychiatric comorbidity (e.g., psychosis, schizophrenia, dissociative state); Known contraindication to lidocaine use which include current symptomatic or clinically significant brady- or tachyarrhythmia, systolic blood pressure \<90 or \>180 mmHg; Scheduled interventions targeting neuropathic pain: epidural injections, peripheral nerve blocks, Bier block, radiofrequency of dorsal root ganglia and peripheral nerves, additional lidocaine or ketamine infusions; Newly added analgesic or neuromodulating medications within 30 days; Recently performed neuromodulating interventions within 90 days; Previous lidocaine-ketamine, lidocaine or ketamine infusion within 6 months; Acute intoxication or active illegal substance abuse;
Canadian sites (1)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04123652